Nanomedicine

PB/PK for nanomedicine
is far behind.

Conventional PB/PK was built around small molecules. The heuristics it relies on don't describe how nanoparticles actually distribute, accumulate, or clear in humans — so failure modes that should have been caught in silico end up surfacing in the clinic.

By 2030, the global nanomedicine market will exceed $410 billion1

Targeted therapeutics, mRNA delivery systems, and tumour-homing nanoparticles are rapidly moving into clinical pipelines, with a year on year increase of 12%. Soon nanoparticles will be a mainstream pillar of modern drug development.

But only around 90 nanomedicines have ever been approved. Pre-clinical models that work for small molecules systematically mispredict how nanoparticles distribute, accumulate, and clear in humans — leaving billions of dollars of clinical work exposed to surprises that should have been caught much earlier.

PB/PK will be one of nanomedicine's biggest challenges

Lipinski's Rule of 5

  • Less than 5 H-bond donors
  • Less than 10 H-bond acceptors
  • Molar mass less than 500 Da
  • C log P less than 5

Rules of 5 and other heuristics don't work for nanomedicine.

Most of the big improvements in PK related failures are due to heuristics. We desperately need to rethink PB/PK for the future of medicine.

We build with nanomedicine in mind from the start

Multivalency

The attachment and selectivity of nanoparticles is drastically affected by multivalent binding. Our models allow us to easily capture the effect of multivalent binding, incorporating the underlying thermodynamics of the interactions.

Endocytosis

Endocytosis and transcytosis are not trivial for nanoparticles. We are able to account for accumulation, sterics, deformation, and a whole other range of endocytosis related phenomenna.

BBB

Nanoparticles behave very differently with regard to the blood brain barrier than other species. Our models allow us to readily account for this, helping you better understand delivery into the brain.

Find out how we can help your drug get to market.

Informed Kinetics